# ‘Cicada’ COVID Variant BA 3.2 Spreads to 25 States: What Symptoms You Should Not Ignore
As India continues its journey towards normalcy, a new sub-lineage of the Omicron variant, colloquially dubbed ‘Cicada’ or BA 3.2, has emerged as a topic of public health concern. Reports indicate that this variant has now spread to 25 states across the country, prompting renewed calls for vigilance. While the nation has largely moved past the more severe phases of the pandemic, understanding the characteristics and symptoms of newer variants like BA 3.2 is crucial for maintaining collective health and preventing potential surges. This article delves into what makes ‘Cicada’ noteworthy and, more importantly, what symptoms individuals should be particularly attentive to.
The ‘Cicada’ Variant: Understanding BA 3.2
BA 3.2 is a sub-lineage of the highly transmissible Omicron variant, which has been the dominant strain globally for some time. Like its parent, BA 3.2 appears to exhibit increased transmissibility, leading to its rapid spread across a significant number of Indian states. The moniker ‘Cicada’ is a popular term, often used to refer to its pattern of emergence or its perceived characteristics, distinguishing it in public discourse from its more technical designation.
While early data suggests that BA 3.2 generally causes milder illness compared to earlier, more aggressive variants like Delta, particularly in vaccinated individuals, its widespread circulation still poses a risk, especially to vulnerable populations such as the elderly, those with comorbidities, and the unvaccinated. Public health officials are closely monitoring its trajectory, noting that while hospitalisation rates have not seen a dramatic spike proportionate to its spread, the potential for a burden on healthcare infrastructure remains if precautions are neglected. The variant’s ability to evade existing immunity from previous infections or vaccinations, though not entirely, means breakthrough infections are possible, underscoring the need for continued awareness.
Key Symptoms of Cicada (BA 3.2) You Should Not Ignore
Understanding the symptom profile of BA 3.2 is paramount for early detection and isolation, which are critical steps in breaking the chain of transmission. While many symptoms overlap with those of the common cold or flu, given the current context, it is wise to consider any new onset of these signs as potentially COVID-19 related and act accordingly.
Here are the key symptoms associated with the ‘Cicada’ variant that warrant attention:
* Fever and Chills: A rise in body temperature, often accompanied by shivering, remains a common indicator.
* Persistent Cough: This is frequently a dry cough, but can sometimes be productive. It’s important to note if the cough persists for several days.
* Sore Throat: A scratchy or painful throat is a very common complaint with Omicron sub-variants, including BA 3.2.
* Fatigue and Weakness: Feeling unusually tired or lacking energy, even after sufficient rest, is a significant symptom that can sometimes linger.
* Body Aches: General muscle pain or a feeling of overall discomfort in the body.
* Headache: Mild to severe headaches have been reported.
* Nasal Congestion or Runny Nose: Symptoms similar to a common cold, making differentiation challenging without testing.
* Gastrointestinal Issues: Nausea, vomiting, and diarrhoea are also increasingly reported with newer variants and should not be dismissed.
* Loss of Taste or Smell: While less common with Omicron sub-variants than with earlier strains, it can still occur in some cases.
It is critical to remember that symptoms can vary in intensity. For vaccinated individuals, the illness might feel like a mild cold, but the potential for transmission remains.
Staying Ahead: Prevention and Public Health Advisories
As the ‘Cicada’ variant continues its spread, experts reiterate the importance of established public health measures. “While BA 3.2 may present with milder symptoms for many, especially vaccinated individuals, it is crucial not to become complacent,” advises Dr. Rakesh Sharma, a leading epidemiologist based in Mumbai. “Early testing and isolation remain our strongest tools to prevent further community transmission and protect vulnerable populations.”
Vaccination, including booster doses when eligible, remains the most effective defence against severe illness and hospitalisation. Additionally, consistent adherence to basic hygiene practices—such as frequent hand washing, wearing masks in crowded indoor spaces, and maintaining physical distancing—plays a vital role in curbing the spread. Anyone experiencing symptoms, even mild ones, should self-isolate and get tested promptly to confirm their status and prevent unknowingly transmitting the virus to others. State governments, in collaboration with central health authorities, are reinforcing surveillance and genomic sequencing efforts to track the variant’s evolution and spread.
The spread of the ‘Cicada’ BA 3.2 variant across 25 states underscores the dynamic nature of the COVID-19 pandemic. While the situation does not currently point to a return to severe lockdowns, it serves as a crucial reminder for sustained vigilance. Recognizing the key symptoms, especially those that mimic common ailments, is essential for prompt action. By staying informed, adhering to preventive measures, and prioritising testing when symptoms appear, India can collectively navigate this new development and continue to protect public health.
